Compare Aecom (ACM) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aecom vs Revvity Inc — how do they compare? Aecom trades at $61.25 (market cap $8.62B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Revvity Inc is the larger of the two by market cap, and Aecom pays the higher dividend (1.77%). Which is the better fit depends on your goals.
| ACM | RVTY | |
|---|---|---|
Market Cap | $8.62B | $12.91B |
Sector | Industrials | Technology |
52-Week High | $134.35 | $117.75 |
52-Week Low | $66.86 | $82.26 |
Enterprise Value | $10.81B | $15.23B |
Dividend Yield | 1.77% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACM's stock declined 16.73% to $61.04 amid a Q2 2026 earnings miss, reporting a loss of $0.50 per share versus expectations of $1.46. Despite the recent setback, the company maintains strong analyst support with a 64% buy rating and $88.25 consensus price target. Technical indicators show bearish momentum with the stock trading near key support levels, while fundamentals reveal mixed performance with positive revenue growth but negative ROE and ROA metrics.
The outlook remains cautiously optimistic given the significant analyst upside potential, though investors face near-term volatility from project execution challenges and ongoing securities investigation. Long-term infrastructure demand provides growth tailwinds, but recent earnings volatility and negative profitability ratios warrant careful monitoring of operational improvements.
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
